Drug Approval | March 13, 2023
Shilpa Medicare gets 2 minor observations from USFDA for Unit VII, Analytical Services Division
The company will be submitting the responses to US FDA observations within stipulated timeline
The company will be submitting the responses to US FDA observations within stipulated timeline
eSanjeevani 2.0 will enhance the telemedicine experience further with a plethora of new features both in terms of technology as well as innovation
India is working towards augmenting health infrastructure and have initiated multiple schemes to strengthen health systems and improve health service delivery
The company has been issued ‘Form 483’ with two observations
India's G20 Presidency will focus on three main priorities: Health Emergencies Prevention, Preparedness and Response (One Health & AMR); Access and Availability to Affordable Medical Countermeasures (Vaccines, Therapeutics, and Diagnostics); and Digital Health
The company will respond to these observations within the stipulated time period.
A First of its Kind Initiative in Mahbubnagar District for Medical Officers, ANM, Anganwadi workers for prevention of Thalassemia and Sickle Cell anemia as part of Antenatal screening of pregnant women project
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
The newly built centre will work as the state-of-the-art facility for not just ethical animal studies but spans from basic, applied to regulatory animal research.
Subscribe To Our Newsletter & Stay Updated
